NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note published on Tuesday morning. The firm issued a hold rating on the stock.

NovaBay Pharmaceuticals Stock Performance

NYSE NBY opened at $0.61 on Tuesday. The firm’s 50 day moving average price is $0.65 and its two-hundred day moving average price is $0.63. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $9.08. The stock has a market cap of $3.54 million, a price-to-earnings ratio of -0.01 and a beta of 0.73.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.